Navitor Pharmaceuticals Inc.
Targeting mTORC1 to treat disease
This article was originally published in Start Up
Executive Summary
Navitor Pharmaceuticals Inc.’s drug discovery efforts are focused on producing compounds that can selectively dampen or bolster mTORC1 activity. Increased activity of mTORC1 has been linked to metabolic, autoimmune, neurodegenerative, and chronic inflammatory diseases.